RE:RE:RE:RE:Part of an E-Mail from MP Todaymenoalittle wrote: Negotiating any JV from a position of attained BTD, the significantly increasing potential of Rutherrin, and a relatively low total outstanding share count is not only going to outweigh any position of weakness that TLT might currently be perceived being in, but it is going to MORE than compensate us extremely well for the temporary discomfort of having had our share priced capped for as long as it's been...
"The significance of VC funding in propelling biotech companies toward commercialization is frequently underappreciated. VC investment often serves as the crucial financial backbone for these fledgling companies. An astonishing 98% of deal value (and 86% of the total number of deals) in the pharmaceutical sector is attributed to VC-backed companies. -- VC investors are known for their willingness to commit substantial funds to companies that show high growth potential, notwithstanding the inherent risk involved. This capital infusion enables biotech and small pharma to maintain operations, propel research and development endeavors and adeptly navigate the regulatory landscape."